Navigation Links
Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology
Date:3/15/2010

oherence tomography (OCT), and other state-of-the-art invasive and non-invasive imaging modalities at six, 12, 18 and 24 months.

Abbott's bioresorbable technology delivers everolimus, a drug that inhibits tissue proliferation. Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its vascular devices. Everolimus has been shown to inhibit treated site neointimal growth in the coronary vessels following vascular device implantation, due to its anti-proliferative properties.

About Abbott Vascular

Abbott Vascular is a global leader in cardiac and vascular care with market-leading products and an industry-leading pipeline. Abbott Vascular offers a comprehensive cardiac and vascular devices portfolio, including products for coronary artery disease, vessel closure, endovascular disease, and structural heart disease.

About Abbott

Ab
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Novastem, a ... its first patient in its study for ischemic ... American Stroke Association, ischemic strokes account for 87 ... enroll qualified patients in the study, entitled "Internal ... of Allogeneic Mesenchymal Stem Cells and Intrathecal Administration ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today that on December 24, 2014 ... The Company raised approximately $2.3 million ... to use the net proceeds from the offering ...
(Date:12/24/2014)... and LONDON , December ... orthopedic industry are expected to grow at an average ... terms of value and volume. Hip, knee and spine ... world while in emerging economies they have a lower ... are challenging the use of composites. Non-metallic orthopedic devices ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... Nov. 3, 2011 Dyadic International, Inc. ("Dyadic") ... on the discovery, development, manufacture and sale of ... enzyme and biopharmaceutical industries, today announced financial results ... (Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO) The financial information ...
... VIVUS, Inc. (NASDAQ: VVUS ) today announced that ... the peer-reviewed journal of The Obesity Society. The EQUIP study ... 1,267 severely obese (BMI >/= 35 kg/m 2 ) patients across ... of 14.4% of initial body weight among those who completed the ...
Cached Medicine Technology:Dyadic International Reports 2011 Third Quarter Financial Results 2Dyadic International Reports 2011 Third Quarter Financial Results 3Dyadic International Reports 2011 Third Quarter Financial Results 4Dyadic International Reports 2011 Third Quarter Financial Results 5Dyadic International Reports 2011 Third Quarter Financial Results 6Dyadic International Reports 2011 Third Quarter Financial Results 7Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 3Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 4Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 5Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 6
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... complex chronic illnesses can receive effective, less expensive care from ... access to a team of dedicated health care professionals, a ... seriously ill and need either hospitalization or a trip to ... medical home clinic at the University of Texas in Houston ...
(Date:12/25/2014)... is common during the holidays, but there are strategies that ... "Don,t arrive at a party hungry. It may seem logical ... a party, but deprivation leads to hunger, and hunger leads ... in Mount Kisco, N.Y., said in a hospital news release. ... even to have a snack before attending a party when ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 ... "fountain of youth" drug that can delay the effects of ... study suggests. Seniors received a significant boost to their ... signaling pathway linked to aging and immune function, researchers with ... medication, a version of the drug rapamycin, improved the seniors, ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number of ... District of West Virginia, Bernstein Liebhard LLP reports. According ... Court is scheduled to convene a Joint Status Conference ... at 10:00 a.m. Parties have been directed to submit ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios ... customizable business presentation tool made specifically for Final ... business tool, users can now display their stats and ... Film Studios. “ProFire 5k gives users a multiple options ... to a presentation” , Pixel Film Studios takes the ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... U.S. has enough capacity for typical season; experts less sure ... The current swine flu outbreak is raising critical questions about ... the logistics of getting it to the people who need ... cut into this fall,s production of seasonal influenza vaccine, experts ...
... 2nd Annual Disability Leadership & Policy Summit: ... to promote an exchange of ideas between people with disabilities ... health and human service professionals will convene on Wednesday, June ... speakers and their topics include: , , ...
... own, while most Americans agree both are equally ... has contributed to poorer overall family health and ... to healthcare. Two-thirds of Americans (66 percent) believe ... care of their health and their children,s health. ...
... Costs by Reducing UtilizationCOLUMBUS, Ohio, May 18 As ... healthcare costs, Quantum Health, Inc. announced that its Coordinated ... employee, or 14%, in 2008. Over the past ten ... to 4%-5% with no reduction in benefits or cost-shifting ...
... to improve navigation, functionality and user-friendliness. The new website still ... with better design and navigation, users can now access information, ... ... Neptune Beach, FL (PRWEB) May 18, 2009 ...
... NewCardio,s platform technology delivers new levels of analysis ... May 18 NewCardio, Inc., (OTC Bulletin Board: ... announced that members of the Company,s medical and ... clinical data from analytical and clinical applications of ...
Cached Medicine News:Health News:Adequate Supply of Swine Flu Vaccine Uncertain 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 3Health News:United Spinal Association's 2nd Annual Disability Leadership & Policy Summit: Health Issues and People with Disabilities 2Health News:New Research Finds Recession Has Greater Impact on Health of Parents Than Children 2Health News:New Research Finds Recession Has Greater Impact on Health of Parents Than Children 3Health News:Coordinated Health/Care(TM) Saves Participating Employers $1000+ per Employee in 2008 2Health News:Coordinated Health/Care(TM) Saves Participating Employers $1000+ per Employee in 2008 3Health News:Coordinated Health/Care(TM) Saves Participating Employers $1000+ per Employee in 2008 4Health News:International Student Insurance Announces Website Redesign 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 3Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 4Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: